The University of Texas MD Anderson Cancer Center’s Research Highlights provides a glimpse into recently published studies in basic, translational and clinical cancer research from MD Anderson experts. Current advances include new targeted therapy approaches for chronic lymphocytic leukemia (CLL) and acute myeloid leukemia (AML), predicting survival following follicular lymphoma treatment, understanding how AML responds to checkpoint...
Anil Sood, M.D., professor of Gynecologic Oncology and Reproductive Medicine, has been elected to the National Academy of Medicine (NAM) for...
In a first-in-human, Phase I trial, researchers at The University of Texas MD Anderson Cancer Center discovered that ATR inhibitor RP-3500...
The University of Texas MD Anderson Cancer Center and Schrödinger, Inc. today announced a two-year strategic research collaboration focused on accelerating and optimizing the development of Schrödinger’s WEE1 inhibitor program, an investigational therapeutic approach designed to target the WEE1 kinase.
The collaboration brings together the translational research and drug development expertise of MD Anderson’s Therapeutics...
The University of Texas MD Anderson Cancer Center’s Research Highlights provides a glimpse into recently published studies in basic, translational...
The University of Texas MD Anderson Cancer Center today named Caroline Chung, M.D., associate professor of Radiation Oncology and Diagnostic...
The University of Texas MD Anderson Cancer Center and the Rare Cancer Research Foundation today announced the launch of a collaboration designed...
The University of Texas MD Anderson Cancer Center and Siemens Healthineers today announced the collaborative development of a global education...
The University of Texas MD Anderson Cancer Center and BostonGene Corporation today announced a strategic alliance to advance the development...
The University of Texas MD Anderson Cancer Center is proud to support World Cancer Research Day, Sept. 24, and its efforts to promote cancer...